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BSTRACT
 
Background and Methods
 
Hereditary hemochro-
matosis is associated with homozygosity for the
C282Y mutation in the hemochromatosis 
 
(HFE)
 
 gene
on chromosome 6, elevated serum transferrin satu-
ration, and excess iron deposits throughout the
body. To assess the prevalence and clinical expres-
sion of the 
 
HFE
 
 gene, we conducted a population-
based study in Busselton, Australia. In 1994, we ob-
tained blood samples for the determination of serum
transferrin saturation and ferritin levels and the pres-
ence or absence of the C282Y mutation and the
H63D mutation (which may contribute to increased
hepatic iron levels) in 3011 unrelated white adults.
We evaluated all subjects who had persistently ele-
vated transferrin-saturation values (45 percent or
higher) or were homozygous for the C282Y muta-
tion. We recommended liver biopsy for subjects with
serum ferritin levels of 300 ng per milliliter or higher.
The subjects were followed for up to four years.
 
Results
 
Sixteen of the subjects (0.5 percent) were
homozygous for the C282Y mutation, and 424 (14.1
percent) were heterozygous. The serum transferrin
saturation was 45 percent or higher in 15 of the 16
who were homozygous; in 1 subject it was 43 per-
cent. Four of the homozygous subjects had previous-
ly been given a diagnosis of hemochromatosis, and
12 had not. Seven of these 12 patients had elevated
serum ferritin levels in 1994; 6 of the 7 had further
increases in 1998, and 1 had a decrease, although the
value remained elevated. The serum ferritin levels in
the four other homozygous patients remained in the
normal range. Eleven of the 16 homozygous subjects
underwent liver biopsy; 3 had hepatic fibrosis, and
1, who had a history of excessive alcohol consump-
tion, had cirrhosis and mild microvesicular steatosis.
Eight of the 16 homozygous subjects had clinical
findings that were consistent with the presence of
hereditary hemochromatosis, such as hepatomegaly,
skin pigmentation, and arthritis.
 
Conclusions
 
In a population of white adults of
northern European ancestry, 0.5 percent were ho-
mozygous for the C282Y mutation in the 
 
HFE
 
 gene.
However, only half of those who were homozygous
had clinical features of hemochromatosis, and one
quarter had serum ferritin levels that remained nor-
mal over a four-year period. (N Engl J Med 1999;341:
718-24.)
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EREDITARY hemochromatosis is a com-
mon inherited disorder of iron metabo-
lism.
 
1-4
 
 Recently, a new major-histocom-
patibility-complex class I–like candidate
gene (
 
HFE
 
) for hereditary hemochromatosis contain-
ing two missense mutations was identified on chro-
mosome 6.
 
5
 
 A single mutation (G to A at nucleotide
845) in the 
 
HFE
 
 gene results in the substitution of
tyrosine for cysteine at amino acid 282 and is termed
the C282Y mutation. A second mutation (C to G at
nucleotide 187) in the 
 
HFE
 
 gene results in the sub-
stitution of aspartate for histidine at amino acid 63
and is termed the H63D mutation. These mutations
are usually detected by restriction-enzyme digestion
after amplification of DNA with the polymerase chain
reaction (PCR). The C282Y mutation results in the
formation of a unique 
 
Sna
 
BI restriction site, whereas
the H63D mutation results in the loss of a 
 
Dpn
 
II site.
Homozygosity for the C282Y mutation is found
in 85 to 90 percent of patients of northern Europe-
an origin who have typical hereditary hemochroma-
tosis.
 
3,5-14
 
 Fifteen to 20 percent of the patient popu-
lation is heterozygous for the H63D mutation. This
mutation may contribute to increased hepatic iron
levels but does not result in iron overload in the ab-
sence of the C282Y mutation.
 
3,15,16
 
 The diagnosis of
overt hereditary hemochromatosis is usually based
on clinical features, elevated serum transferrin satu-
ration, elevated ferritin levels, characteristic findings
on liver biopsy, and elevated hepatic iron levels.
 
17
 
Measurement of transferrin saturation is the single
best screening test.
 
2,18-20
 
The degree to which the hemochromatosis muta-
tion affects the development of iron overload and
clinical disease is unknown.
 
21
 
 Recent family studies of
subjects of known genotype with hereditary hemo-
chromatosis have shown that in up to 26 percent of
subjects who are homozygous for the C282Y muta-
tion, iron overload may not develop.
 
22,23
 
 These stud-
ies suggest that rates of expression of the disease may
H
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be variable and lower than previously believed. We
conducted a population-based study to determine
the prevalence of the C282Y mutation, the frequen-
cy of the clinical expression of iron overload, and
genotype–phenotype correlations over a four-year
period.
 
METHODS
 
Subjects
 
Busselton is a town in the southwestern region of Western Aus-
tralia, with a population of 10,888 in 1994. The residents are pre-
dominantly of Anglo-Celtic descent. They have been prospectively
studied since 1966 and, in many respects, are similar to the pop-
ulation of Framingham, Massachusetts.
 
24,25
 
 The most recent fol-
low-up study of this population was performed in 1994. At this
evaluation of approximately 5000 white subjects, clinical assess-
ment was performed and whole-blood and serum samples were
obtained while the subjects were fasting. From this group, we ran-
domly selected a sample of 3011 unrelated subjects, 20 to 79 years
old. The predicted rates of prevalence of heterozygosity and ho-
mozygosity for the C282Y mutation in this sample were 8 percent
(95 percent confidence interval, 7 to 9 percent) and 0.3 percent
(95 percent confidence interval, 0.1 to 0.6 percent), respectively.
 
1
 
Clinical, biochemical, and genotypic information was collected
for all the subjects. Only in cases in which the serum transferrin
saturation was elevated (»45 percent) were the data on the sub-
jects reviewed by one of the investigators and the serum iron
studies repeated while the subjects were fasting. All subjects with
persistently elevated transferrin-saturation values and those who
were homozygous for the C282Y mutation underwent clinical
evaluation. Liver biopsy was recommended if the serum ferritin
level was 300 ng per milliliter or higher. 
Informed consent was obtained before the biopsies were per-
formed. The Busselton Population Medical Research Foundation
and the Committee for Human Rights at the University of West-
ern Australia granted us permission to conduct the study.
 
Measurement of Serum Iron, Transferrin, and Ferritin
 
Serum iron levels were measured by a standard colorimetric
method, and serum transferrin levels were determined by rate im-
munoturbidimetry on an automated analyzer (model 917, Hita-
chi, Tokyo, Japan). Serum transferrin-saturation values were cal-
culated as follows: ([serum iron÷2]¬serum transferrin)¬100.
Serum ferritin levels were measured by chemiluminescence im-
munoassay (ACS-180, Chiron Diagnostics, Norwood, Mass.). He-
patic iron levels were measured as previously described.
 
26
 
Identification of the C282Y and H63D Mutations 
in the 
 
HFE
 
 Gene
 
DNA was extracted from spots of whole blood collected on
neonatal-type screening cards, as described by Singer-Sam and
Tanguay.
 
27
 
 PCR amplification of the regions containing the mis-
sense mutations was performed with the primer sequences of
Feder et al.
 
5
 
 (GenBank accession number U60319) and the cy-
cling conditions described by Cullen et al.
 
28
 
 The C282Y and
H63D mutations were identified with use of restriction-enzyme
digestion, followed by analysis on a 3 percent agarose gel. The
status of all subjects homozygous for the C282Y mutation was
confirmed with the use of the primer sequence of Jeffrey et al.
 
29
 
Only subjects with a single C282Y mutation or persistently
elevated serum iron levels underwent genotyping for the H63D
mutation.
 
Statistical Analysis
 
All values are presented as means ±SD unless otherwise spec-
ified. Comparisons between groups were made with the Mann–
Whitney U test.
 
30
 
 All P values are two-tailed.
 
RESULTS
 
Characteristics of the Subjects
 
The age and sex of the subjects are shown in Table
1. There were 1491 women and 1520 men, with an
age range of 20 to 79 years. Four subjects (two men
and two women) were being treated for hemochro-
matosis at the time of the study.
 
Serum Transferrin Saturation and Ferritin Levels
 
The frequency distributions of the serum transfer-
rin-saturation values and serum ferritin levels are
shown in Figure 1. The serum transferrin saturation
had a normal distribution in both men and women,
whereas the serum ferritin levels had a skewed dis-
tribution. One hundred thirty-five men and 57 wom-
en had transferrin-saturation values of 45 percent or
higher; 343 men and 62 women had ferritin levels
of 300 ng per milliliter or higher. Forty men and six
women had both serum transferrin-saturation values
of 45 percent or higher and serum ferritin levels of
300 ng per milliliter or higher.
 
Hemochromatosis Genotypes
 
The prevalence rates for the C282Y and H63D
mutations are shown in Tables 2 and 3. Subjects
were grouped according to whether or not they had
serum transferrin-saturation values of 45 percent or
higher (Table 2) and whether or not they had serum
ferritin levels of 300 ng per milliliter or higher (Table
3). There were 16 subjects with the C282Y/C282Y
genotype (0.5 percent), 359 with the C282Y/wild-
type genotype (11.9 percent), and 65 with the
C282Y/H63D genotype (2.2 percent). The remain-
ing 2571 subjects did not have the C282Y mutation
(those with the wild-type/wild-type genotype).
Of the 192 subjects with transferrin-saturation
values of 45 percent or higher in 1994, 15 had the
C282Y/C282Y genotype, 38 had the C282Y/wild-
type genotype, 14 had the C282Y/H63D genotype,
and 125 had the wild-type/wild-type genotype (Ta-
ble 2). In 1994, one 53-year-old homozygous man
had a serum transferrin-saturation value of 43 percent
and a serum ferritin level of 647 ng per milliliter; in
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Median (yr) 52 53
Age group (no.)
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60–69 yr
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132
275
313
286
294
220
120
220
284
294
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1998, he had a serum transferrin-saturation value of
102 percent and a serum ferritin level of 731 ng per
milliliter (Subject 1, Table 4). He had no history of
blood donation or blood loss at the time of the ini-
tial testing.
Only 35 of the 192 subjects with elevated trans-
ferrin-saturation values in 1994 had persistently ele-
vated transferrin-saturation values. Of these 35, 15
had the C282Y/C282Y genotype (Subjects 2 through
16 in Table 4), 5 had the C282Y/wild-type geno-
type, 1 had the C282Y/H63D genotype, and 14 had
the wild-type/wild-type genotype. Thus, the sensi-
tivity, specificity, and positive predictive value of a
single serum transferrin-saturation value of 45 per-
cent or higher (measured while the subject was fast-
ing) for the detection of C282Y homozygosity were
94 percent, 94 percent, and 6 percent, respectively.
Of the 405 subjects who had serum ferritin levels
of 300 ng per milliliter or higher in 1994, 8 had the
C282Y/C282Y genotype, 47 had the C282Y/wild-
type genotype, 22 had the C282Y/H63D genotype,
and 328 did not have the C282Y mutation (Table
3). Thus, the sensitivity, specificity, and positive pre-
dictive value of a serum ferritin level of 300 ng per
milliliter or higher for the detection of C282Y homo-
zygosity were 50 percent, 87 percent, and 2 percent,
 
Figure 1.
 
 Frequency Distributions of Transferrin-Saturation (Panel A) and Ferritin Levels (Panel B) in
Blood Samples Obtained from the Busselton, Australia, Population in 1994.
Each bar represents cumulative data for the preceding 10-percent range for transferrin saturation or
the preceding 50-ng-per-milliliter range for ferritin.
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respectively. When the four subjects who were un-
dergoing treatment for hemochromatosis at the time
of the study were excluded from the analysis of serum
ferritin levels, the sensitivity, specificity, and positive
predictive value were 75 percent, 87 percent, and
2 percent, respectively. Nine subjects had a persist-
ently elevated serum ferritin level (300 ng per milli-
liter or higher) and a serum transferrin-saturation
value of 45 percent or less.
 
Serum Iron Levels, Sex, and Genotype
 
Men and women with the C282Y/H63D geno-
type had significantly higher serum transferrin-satu-
ration values (41±15 percent and 36±11 percent,
respectively) than men and women with either the
C282Y/wild-type genotype (32±11 percent and
28±12 percent, respectively) or the wild-type/wild-
type genotype (30±11 percent and 26±14 percent,
respectively; P<0.001). Men with the C282Y/H63D
genotype had significantly higher serum ferritin lev-
els (351±191 ng per milliliter) than men with the
C282Y/wild-type genotype (217±173 ng per milli-
liter) or the wild-type/wild-type genotype (221±
263 ng per milliliter, P<0.001). There was a trend
toward higher serum ferritin levels in women with
the C282Y/H63D genotype than in those with the
C282Y/wild-type or wild-type/wild-type genotype
(P=0.07). Men and women who were homozygous
for the C282Y mutation had similar serum trans-
ferrin-saturation values (80±24 percent and 70±16
percent, respectively); the serum ferritin levels in the
men were higher than those in the women but were
not significantly different (609±55 ng per milliliter
and 334±387 ng per milliliter, respectively).
 
Clinical Characteristics of the Subjects Who Were 
Homozygous for the C282Y Mutation
 
Of the 16 subjects with the C282Y/C282Y gen-
otype, 12 had not previously received a diagnosis of
hemochromatosis (Table 4). In 1994, 7 of these 12
subjects had elevated serum ferritin levels (»300 ng
per milliliter or higher); 6 of these 7 (Subjects 1, 2,
7, 8, 9, and 10) had further increases during the
four-year follow-up period, and 1 (Subject 4) had a
decrease although the value remained elevated. Four
subjects (Subjects 3, 5, 11, and 12) had normal se-
rum ferritin levels that did not increase substantially
during the four-year follow-up period; none had a
history of blood donation, gastrointestinal bleeding,
or malabsorption of food. Two subjects without an
increase in serum ferritin levels over the four-year
period (Subjects 4 and 5) had hepatic iron levels
above the normal range (reference range in our lab-
oratory, «20 µmol per gram of liver, dry weight).
Clinical features that are consistent with the diag-
nosis of hereditary hemochromatosis were present at
the time of diagnosis in 8 of the 16 subjects. Eleven
of the 16 underwent liver biopsy. Three of the five
who did not (Subjects 3, 11, and 12) did not meet
the criteria for liver biopsy and had serum ferritin
levels of 100 ng per milliliter or less. Two subjects
(Subjects 6 and 9) met the criteria for liver biopsy
but declined to undergo the procedure. All subjects
who underwent liver biopsy had a hepatic iron level
above the upper limit of the normal range. Three sub-
jects had a hepatic iron index of 1.9 or less (Subjects
1, 4, and 5). Three subjects had hepatic fibrosis, and
one had cirrhosis; the patient with cirrhosis also had
 
*Only subjects with elevated transferrin-saturation values in 1994 under-
went another test four years later.
†CI denotes confidence interval.
‡In addition, a 53-year-old man with newly diagnosed hemochromatosis
had a serum transferrin saturation of 43 percent and a serum ferritin level
of 647 ng per milliliter in 1994. Before liver biopsy in 1998, his serum
transferrin saturation was 102 percent, and his serum ferritin level was 731
ng per milliliter. Four of the subjects who were homozygous for the C282Y
mutation had received a diagnosis of hereditary hemochromatosis before
the study and were undergoing treatment.
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1994 1998
 
no. (95% CI)†
 
Wild type/wild type 2571 125 (105–149) 14 (8–23)
C282Y/wild type 359 38 (27–51) 5 (2–11)
C282Y/H63D 65 14 (8–22) 1 (0–5)
C282Y/C282Y 16 15 (11–16)‡ 16 (13–16)
Total 3011 192 36
*CI denotes confidence interval.
†Twelve of 16 subjects who were homozygous for
the C282Y mutation received a diagnosis of hemo-
chromatosis in 1994; 7 of the 12 had ferritin levels
of 300 ng per milliliter or higher.
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Wild type/wild type 2571 328 (282–359)
C282Y/wild type 359 47 (36–61)
C282Y/H63D 65 22 (15–30)
C282Y/C282Y† 16 8 (4–12)
Total 3011 405
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mild microvascular steatosis and a history of excessive
alcohol consumption (>60 g per day). None of the
other homozygous subjects had a history of chronic
viral hepatitis or excessive alcohol consumption.
 
Clinical Characteristics of the Subjects with Elevated Iron 
Levels Who Were Not Homozygous for the C282Y 
Mutation
 
Eleven subjects who were not homozygous for
the C282Y mutation had serum transferrin-satura-
tion values of 45 percent or higher and serum ferritin
levels of 300 ng per milliliter or higher. Two of these
subjects had recognizable clinical conditions resulting
in elevated iron levels: one subject, who was 69 years
old and had the C282Y/wild-type genotype, had
myelofibrosis, and one, who was 66 years old and had
the wild-type/wild-type genotype, had chronic lym-
phocytic leukemia. Of the other nine subjects, three
between the ages of 38 and 54 years (one with the
C282Y/H63D genotype, one with the C282Y/wild-
type genotype, and one with the wild-type/wild-type
genotype) had grade 3 hepatic iron deposition (de-
fined as 75 to 100 percent of hepatocytes with stain-
able iron deposits
 
31
 
) without fibrosis and are currently
undergoing phlebotomy therapy. Two subjects who
were 66 and 71 years of age (one with the C282Y/
wild-type genotype and one with the wild-type/wild-
type genotype) had no stainable iron or evidence of
liver injury. One 77-year-old subject with the wild-
type/wild-type genotype declined to undergo liver
biopsy and is undergoing phlebotomy therapy. Six
of the nine subjects with elevated iron levels had the
wild-type/wild-type genotype, and all had histories
of excessive alcohol consumption. Thus, the overall
prevalence of clinically significant iron overload among
the subjects who were not homozygous for the
C282Y mutation and who did not have other con-
ditions causing iron overload was 4 in 2995 (0.13
percent). In nine subjects (seven with the wild-type/
wild-type genotype and two with the C282Y/wild-
type genotype) the serum transferrin-saturation val-
ues were 45 percent or higher and the serum ferritin
levels were normal. There was no identifiable cause of
the overload in eight of these subjects; one had chron-
ic lymphocytic leukemia and consumed an excessive
amount of alcohol. In nine subjects (five with the
wild-type/wild-type genotype and four with the
C282Y/wild-type genotype) the serum ferritin levels
were 300 ng per milliliter or higher and the serum
transferrin-saturation values were 45 percent or less.
Three had histories of excessive alcohol consumption,
and one had chronic lymphocytic leukemia.
 
*Subjects with previous diagnoses did not have their iron levels tested again in 1998 as part of this study.
†The hepatic iron index is the hepatic iron level divided by the age in years.
‡Iron grade denotes the degree of iron deposition, as classified by Searle et al.
 
31
 
§Subjects 6 and 9 declined liver biopsy. Subject 9 had lymphoma and had recently been treated with chemotherapy.
 
T
 
ABLE 4. CLINICAL CHARACTERISTICS OF THE SUBJECTS WHO WERE HOMOZYGOUS FOR THE C282Y MUTATION.
SUBJECT
NO.
NEW OR
PREVIOUS
DIAGNOSIS*
AGE IN
1998 (YR) SEX
TRANSFERRIN 
SATURATION
SERUM
FERRITIN
HEPATIC
IRON 
LEVEL
HEPATIC
IRON 
INDEX†
FIBROSIS 
OR
CIRRHOSIS
IRON
GRADE‡ CLINICAL SIGNS
1994 1998 1994 1998
% ng/ml µmol/g
1 New 57 M 43 102 647 731 100 1.7 No 3 Pigmentation, arthritis,
hepatomegaly
2 New 57 F 57 75 510 660 166 2.7 No 3 Arthritis
3 New 41 F 63 62 44 60 — — — — None
4 New 74 M 68 55 564 526 95 1.2 Fibrosis 3 Arthritis
5 New 45 F 70 63 189 187 69 1.4 No 1 None
6§ New 35 F 83 95 145 805 — — — — None
7 New 50 M 100 100 1677 2290 381 7.2 Cirrhosis 4 Pigmentation, hepato-
megaly
8 New 42 M 113 97 606 790 796 17.3 Fibrosis 4 Pigmentation, arthritis
9§ New 73 F 105 77 870 1200 — — — — None
10 New 42 M 90 46 694 868 311 7.4 No 3 None
11 New 30 F 56 75 14 32 — — — — None
12 New 43 F 62 76 25 28 — — — — None
13 Previous 58 F 71 1047 295 4.8 No 4 Pigmentation, arthritis
14 Previous 35 M 82 31 289 7.8 No 3 Pigmentation, arthritis,
hepatomegaly
15 Previous 55 M 62 44 280 6.0 Fibrosis 4 None
16 Previous 40 F 63 159 80 2.0 No 2 Pigmentation
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DISCUSSION
We evaluated the penetrance of the C282Y muta-
tion in the HFE gene in a population study that was
not based on blood-bank data. In our sample of
3011 white Australians, 0.5 percent of the subjects
were homozygous for the mutation. Twelve percent
had the C282Y/wild-type genotype, and 2 percent
had the C282Y/H63D genotype. The frequency of
heterozygosity for the C282Y mutation in our sam-
ple (0.141) was consistent with the frequency that
would be predicted with the Hardy–Weinberg equa-
tion (0.135), on the basis of an allelic frequency of
0.076 for the C282Y mutation. These prevalence
rates for the C282Y mutation are among the highest
that have been reported.2,28,32 There is no evidence
of consanguinity in this population, and it has been
stable, with minimal migration in or out of the re-
gion over a period of 30 years.
All 16 subjects with the C282Y/C282Y genotype
had elevated serum transferrin-saturation values or
serum ferritin levels, and all the subjects with this
mutation who underwent liver biopsy had hepatic
iron levels above the upper limit of the normal range.
However, only 8 of the 16 subjects had clinical fea-
tures of hemochromatosis, and 4 had hepatic fibrosis
or cirrhosis. Four subjects had no clinical symptoms
or signs of disease, and their serum ferritin levels
were normal over the four-year follow-up period.
Sixty percent of the subjects with newly diagnosed
hemochromatosis had an increase in iron stores over
the four-year follow-up period, as demonstrated by
the changes in their serum ferritin levels. Four wom-
en (between the ages of 30 and 45 years) did not
have elevated ferritin levels. These data are consis-
tent with the findings reported by Crawford et al.22;
up to 30 percent of the women in their study who
were homozygous for the C282Y mutation did not
have iron overload.
Eleven subjects in our study had elevated serum
transferrin-saturation and ferritin levels but were not
homozygous for the C282Y mutation; 4 of the 11
had evidence of hepatic iron overload and are under-
going phlebotomy treatment. An additional nine sub-
jects had elevated ferritin levels but normal serum
transferrin-saturation values. These subjects may have
disordered iron metabolism, which has been termed
the “dysmetabolic iron overload syndrome,”33 or their
high ferritin levels may be due to an acute-phase
reactant.
The C282Y/H63D genotype (compound heter-
ozygosity) was associated with higher serum iron lev-
els than the C282Y/wild-type or the wild-type/
wild-type genotype. These data provide further sup-
port for a synergistic interaction between the two
mutations.3,15,16
Our data confirm and extend the recent reports of
McLaren et al.20 and Burt et al.2 and indicate that se-
rum transferrin saturation is a more sensitive bio-
chemical marker than the serum ferritin level for the
detection of the C282Y mutation. The sensitivity,
specificity, and positive predictive value of serum
transferrin saturation for the detection of the homozy-
gous C282Y mutation were 94 percent, 94 percent,
and 6 percent, respectively. If the threshold level for
serum transferrin saturation had been set at 50 per-
cent, the sensitivity, specificity, and positive predictive
value would have been 94 percent, 96 percent, and
16 percent, respectively. Since the serum ferritin level
closely reflects total-body iron stores, however, and
since one subject who was homozygous for the
C282Y mutation would not have been identified if
we had relied only on serum transferrin saturation
as a screening test, we recommend that the initial
screening also include measurement of the serum
ferritin level.34
McLaren et al.20 predicted that a serum transferrin-
saturation value of 45 percent or higher, obtained
while the subject was fasting, would identify 98 per-
cent of subjects with homozygous hemochromatosis
but no normal subjects. In their control population,
none of the subjects had a serum transferrin-satura-
tion value of 45 percent or higher. In contrast, we
found that 0.5 percent of subjects with the wild-
type/wild-type genotype had serum transferrin-sat-
uration values above 45 percent. The cause of this
discrepancy is not clear but could be related to dif-
ferences in the populations studied. The population
studied by McLaren et al. was composed of employ-
ees of banks and insurance companies, whereas our
sample was drawn from the general population and
had a wider age range.
Five of the 12 subjects with newly diagnosed ho-
mozygous hemochromatosis had no significant chang-
es in serum transferrin-saturation values or serum
ferritin levels over the four-year study period (Sub-
jects 3, 4, 5, 11, and 12). Two of these subjects (a
woman who was 45 years old and a man who was
74) underwent liver biopsy, and both were found to
have a hepatic iron index below the threshold of 1.9.
The man had hepatic fibrosis. The other three sub-
jects had no symptoms or signs of disease and had
serum ferritin levels of 100 ng per milliliter or lower;
none of them underwent liver biopsy. Although all
the women in this group had normal menstrual cy-
cles, two had excessive postpartum bleeding. Iron
overload develops at a slower rate in women with
hereditary hemochromatosis than in men with the
disorder, because in women iron stores are reduced
during menstruation and pregnancy.34
A cross-sectional study is limited to the evaluation
of data at specific times. Since hemochromatosis is a
disease that changes phenotypically with time, we
used initial screening information from 1994; the
subjects with abnormal test results were evaluated
four years later. This study design eliminated ethical
issues that would have arisen if this had been a pro-
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spective study. Although a four-year follow-up peri-
od is likely to be adequate for the assessment of a
progressive increase in iron stores, as determined by
measurements of serum ferritin levels,33 it is possible
that in some subjects iron overload progressed at a
rate that was too slow to be detected after four years
because of physiologic or pathologic blood loss or
other factors.
Our findings have implications for population
screening for hereditary hemochromatosis and for
identifying the most appropriate initial test. In our
view, the high prevalence of the disorder and the op-
portunity to detect early phenotypic expression and
to intervene and prevent subsequent disease justify
routine screening of asymptomatic white people of
northern European ancestry. The findings of our
study demonstrate that biochemical screening for he-
reditary hemochromatosis identifies virtually all adults
who are homozygous for the C282Y mutation and
who have iron overload. Alternatively, genetic screen-
ing could be performed at birth, with biochemical
follow-up of persons with the homozygous muta-
tion and those with the compound heterozygous
mutation, in order to identify those who would re-
quire treatment. If hemochromatosis is detected be-
fore the age of 40 years and if the serum ferritin level
is less than 1000 ng per milliliter, then hepatic fibro-
sis is very likely to be absent and treatment can be
initiated without the need for liver biopsy.3,15,35,36
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